314 related articles for article (PubMed ID: 26799295)
1. Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab.
Siegal T; Charbit H; Paldor I; Zelikovitch B; Canello T; Benis A; Wong ML; Morokoff AP; Kaye AH; Lavon I
J Neurosurg; 2016 Oct; 125(4):1008-1015. PubMed ID: 26799295
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
3. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
5. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
[TBL] [Abstract][Full Text] [Related]
6. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
7. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
8. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
Hutterer M; Hattingen E; Palm C; Proescholdt MA; Hau P
Neuro Oncol; 2015 Jun; 17(6):784-800. PubMed ID: 25543124
[TBL] [Abstract][Full Text] [Related]
9. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.
Sasayama T; Nishihara M; Kondoh T; Hosoda K; Kohmura E
Int J Cancer; 2009 Sep; 125(6):1407-13. PubMed ID: 19536818
[TBL] [Abstract][Full Text] [Related]
11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
12. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
[TBL] [Abstract][Full Text] [Related]
14. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
16. Serum microRNA is a biomarker for post-operative monitoring in glioma.
Morokoff A; Jones J; Nguyen H; Ma C; Lasocki A; Gaillard F; Bennett I; Luwor R; Stylli S; Paradiso L; Koldej R; Paldor I; Molania R; Speed TP; Webb A; Infusini G; Li J; Malpas C; Kalincik T; Drummond K; Siegal T; Kaye AH
J Neurooncol; 2020 Sep; 149(3):391-400. PubMed ID: 32915353
[TBL] [Abstract][Full Text] [Related]
17. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS
Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Narayana A; Golfinos JG; Fischer I; Raza S; Kelly P; Parker E; Knopp EA; Medabalmi P; Zagzag D; Eagan P; Gruber ML
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):383-9. PubMed ID: 18793954
[TBL] [Abstract][Full Text] [Related]
19. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma.
Guan Y; Chen L; Bao Y; Pang C; Cui R; Li G; Liu J; Wang Y
Int J Clin Exp Pathol; 2015; 8(1):727-34. PubMed ID: 25755767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
